<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723073</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000605/1; BWH</org_study_id>
    <nct_id>NCT00723073</nct_id>
  </id_info>
  <brief_title>Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia</brief_title>
  <official_title>Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive fungal infections are an important cause of morbidity and mortality in patients with
      neutropenia who are receiving chemotherapy for cancer. Early diagnosis of these infections is
      difficult and fever may be the only sign. A delay in treatment while a diagnosis is pursued
      may lead to increased morbidity and mortality. There are now several echinocandins available
      with similar in vitro spectrum of activity. Caspofungin is the only echinocandin Food and
      Drug Administration (FDA) approved for empiric antifungal therapy in febrile neutropenia.
      Although all echinocandin antifungal agents have similar spectrum of activity, there are
      limited data on the use of micafungin in patients with persistent fever and neutropenia (FN).
      In November 2006 the Pharmacy and Therapeutics Committee at Brigham &amp; Women's Hospital / Dana
      Farber Cancer Institute (BWH/DFCI) switched from caspofungin to micafungin as our formulary
      echinocandin. Given the limited clinical data on the use of micafungin as empiric antifungal
      therapy in patients with FN, we sought to evaluate the safety and effectiveness of
      micafungin, compared with caspofungin, for this indication using a sequential cohort analysis
      of patients treated before and after the formulary change at Brigham and Women's Hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

      This retrospective cohort analysis of converting from caspofungin to micafungin as empiric
      antifungal therapy for cancer patients who are persistently febrile and neutropenic after
      receiving broad spectrum antibiotics at Brigham &amp; Women's Hospital / Dana Farber Cancer
      Institute (BWH/DFCI) is designed to evaluate the following objectives:

        -  Safety of micafungin in this patient population

        -  Effective dose of 100 mg daily of micafungin compared to 70mg x1, then 50 mg daily of
           caspofungin

        -  Economic impact of converting or formulary echinocandin from micafungin to caspofungin

      Study Design

        -  Retrospective cohort analysis - limited to medical records

        -  Data to be collected include the following:

             -  Demographic information: including: gender, age, race

             -  Past medical history and admitting diagnoses

             -  Laboratory results: Liver function tests (LFTs), Including alanine aminotransferase
                (ALT), aspartate aminotransferase (AST), Total bilirubin, as well as serum fungal
                assays: Serum Galactomannan assay, 1.3-BD Glucan assay

             -  Concomitant medications and duration of therapy for all systemic: antibiotics and
                antifungals

             -  All invasive breakthrough fungal infection details, including speciation and
                outcomes during echinocandin therapy

             -  Dosing, duration, and adverse events associated with echinocandin therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile Neutropenia (FN)</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful Treatment of Any Baseline Invasive Fungal Disease (IFD)</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality at Hospital Discharge</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>We assessed all patients in the study cohort who dischaged from the hospital alive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of Any Breakthrough Invasive Fungal Disease (IFD)</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed &gt; 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lack of an Adverse Drug Event (ADE) Attributable to Echinocandin (EC) Therapy That Led to Discontinuation of Therapy</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Echinocadin Therapy for Persistent Febrile Neutropenia (FN)</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Tests (LFTs) Elevated During or After Echinocandin Therapy</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&gt; 5x the upper limit of normal (ULN) or total bilirubin &gt; 3x the upper limit of normal (ULN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Type of Adverse Event That Resulted in Echinocandin (EC) Therapy Discontinuation</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitization</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>Median number of days patients were hospitalized during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Neutropenia</measure>
    <time_frame>11/1/2005 - 10/31/2007</time_frame>
    <description>Median number of days patients were neutropenic during the study period</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">323</enrollment>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Caspofungin arm</arm_group_label>
    <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micafungin arm</arm_group_label>
    <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients who are persistently febrile and neutropenic after receiving broad spectrum
        antibiotics and receive empiric antifungal therapy with either caspofungin or micafungin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an
             Absolute Neutrophil Count (ANC) &lt; 500, for persistent febrile neutropenia from
             11/1/2005 - 10/31/2006, as there first antifungal agent.

          -  All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an
             Absolute Neutrophil Count (ANC) &lt; 500 for persistent febrile neutropenia from
             11/1/2006 - 10/31/2007 as there first antifungal agent

        Exclusion Criteria:

          -  Patients receiving an echinocandin antifungal agent (micafungin or caspofungin) for an
             indication other then empiric therapy in febrile neutropenia

          -  Patients receiving therapy for an active or on-going invasive fungal infection

          -  Patients who received both caspofungin and micafungin during the same admission

          -  Patients with an ANC &gt; 500 at when either micafungin or caspofungin was started

          -  Patients who received another antifungal agent for persistent febrile neutropenia,
             e.g., voriconazole, amphotericin B liposome, posaconazole, etc... Before they received
             an echinocandin (caspofungin or micafungin) will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Kubiak, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schuler U, Bammer S, Aulitzky WE, Binder C, Böhme A, Egerer G, Sandherr M, Schwerdtfeger R, Silling G, Wandt H, Glasmacher A, Ehninger G. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie. 2007 Apr;30(4):185-91. Epub 2007 Mar 23.</citation>
    <PMID>17396041</PMID>
  </reference>
  <reference>
    <citation>Toubai T, Tanaka J, Ota S, Shigematsu A, Shono Y, Ibata M, Hashino S, Kondo T, Kakinoki Y, Masauzi N, Kasai M, Iwasaki H, Kurosawa M, Asaka M, Imamura M. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med. 2007;46(1):3-9. Epub 2007 Jan 1.</citation>
    <PMID>17202726</PMID>
  </reference>
  <reference>
    <citation>Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24.</citation>
    <PMID>16048942</PMID>
  </reference>
  <reference>
    <citation>Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 Sep 30;351(14):1391-402.</citation>
    <PMID>15459300</PMID>
  </reference>
  <reference>
    <citation>Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225-34. Erratum in: N Engl J Med. 2007 Feb 15;356(7):760.</citation>
    <PMID>11807146</PMID>
  </reference>
  <reference>
    <citation>Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A; L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000 Nov;31(5):1155-63. Epub 2000 Nov 7.</citation>
    <PMID>11073745</PMID>
  </reference>
  <reference>
    <citation>Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000 Mar;108(4):282-9.</citation>
    <PMID>11014720</PMID>
  </reference>
  <reference>
    <citation>Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999 Mar 11;340(10):764-71.</citation>
    <PMID>10072411</PMID>
  </reference>
  <reference>
    <citation>Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002 Jan 1;34(1):7-14. Epub 2001 Nov 26.</citation>
    <PMID>11731939</PMID>
  </reference>
  <reference>
    <citation>Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 Mar 15;34(6):730-51. Epub 2002 Feb 13.</citation>
    <PMID>11850858</PMID>
  </reference>
  <reference>
    <citation>Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis. 1993 Nov;17 Suppl 2:S487-91. Review.</citation>
    <PMID>8274615</PMID>
  </reference>
  <reference>
    <citation>Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis. 2004 Oct 15;39 Suppl 4:S207-10.</citation>
    <PMID>15546119</PMID>
  </reference>
  <reference>
    <citation>Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008 Jan;46(1):150-6. Epub 2007 Nov 21. Erratum in: J Clin Microbiol. 2008 Sep;46(9):3184-5.</citation>
    <PMID>18032613</PMID>
  </reference>
  <reference>
    <citation>Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007 May 5;369(9572):1519-27.</citation>
    <PMID>17482982</PMID>
  </reference>
  <reference>
    <citation>Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M, Yokozawa T, Baba H, Emi N, Naoe T. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med. 2006;45(5):259-64. Epub 2006 Apr 3.</citation>
    <PMID>16595990</PMID>
  </reference>
  <reference>
    <citation>Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007 Oct 1;45(7):883-93. Epub 2007 Aug 29. Erratum in: Clin Infect Dis. 2008 Jul 15;47(2):302.</citation>
    <PMID>17806055</PMID>
  </reference>
  <reference>
    <citation>Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. Review.</citation>
    <PMID>19724014</PMID>
  </reference>
  <results_reference>
    <citation>Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, Marty FM. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther. 2010 Apr;32(4):637-48. doi: 10.1016/j.clinthera.2010.04.005.</citation>
    <PMID>20435233</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <results_first_submitted>June 7, 2010</results_first_submitted>
  <results_first_submitted_qc>July 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2010</results_first_posted>
  <last_update_submitted>August 25, 2010</last_update_submitted>
  <last_update_submitted_qc>August 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>David W, Kubiak, PharmD, BCPS / Infectious Disease Clinical Specialist</name_title>
    <organization>Brigham and Women's Hospital</organization>
  </responsible_party>
  <keyword>micafungin, caspofungin, febrile neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Caspofungin Arm</title>
          <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
        </group>
        <group group_id="P2">
          <title>Micafungin Arm</title>
          <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caspofungin Arm</title>
          <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
        </group>
        <group group_id="B2">
          <title>Micafungin Arm</title>
          <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="39" upper_limit="58"/>
                    <measurement group_id="B2" value="49" lower_limit="40" upper_limit="58"/>
                    <measurement group_id="B3" value="49" lower_limit="39" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Underlying Disease</title>
          <description>primary oncological diagnosis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute myelogenous leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin's lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute lymphoblastic leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkin's lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic myelogenous leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aplastic anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other onocological diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hematopoietic stem cell transplantation status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hematopoietic stem cell transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No - Hematopoietic stem cell transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Weight, kg</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="67" upper_limit="89"/>
                    <measurement group_id="B2" value="80" lower_limit="65" upper_limit="95"/>
                    <measurement group_id="B3" value="80" lower_limit="65" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile Neutropenia (FN)</title>
        <description>Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy.</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile Neutropenia (FN)</title>
          <description>Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Successful Treatment of Any Baseline Invasive Fungal Disease (IFD)</title>
        <description>Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Treatment of Any Baseline Invasive Fungal Disease (IFD)</title>
          <description>Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Baseline IFD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Successfully treated baseline IFD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsuccessfully treated baseline IFD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>2.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mortality at Hospital Discharge</title>
        <description>We assessed all patients in the study cohort who dischaged from the hospital alive</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality at Hospital Discharge</title>
          <description>We assessed all patients in the study cohort who dischaged from the hospital alive</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive at hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Died before hospitial discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absence of Any Breakthrough Invasive Fungal Disease (IFD)</title>
        <description>a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed &gt; 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Any Breakthrough Invasive Fungal Disease (IFD)</title>
          <description>a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed &gt; 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No breakthrough IFD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breakthrough IFD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lack of an Adverse Drug Event (ADE) Attributable to Echinocandin (EC) Therapy That Led to Discontinuation of Therapy</title>
        <description>Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Lack of an Adverse Drug Event (ADE) Attributable to Echinocandin (EC) Therapy That Led to Discontinuation of Therapy</title>
          <description>Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No ADE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADE which caused EC therapy discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.57</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Echinocadin Therapy for Persistent Febrile Neutropenia (FN)</title>
        <description>median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN)</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Echinocadin Therapy for Persistent Febrile Neutropenia (FN)</title>
          <description>median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN)</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="18"/>
                    <measurement group_id="O2" value="9" lower_limit="6" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Function Tests (LFTs) Elevated During or After Echinocandin Therapy</title>
        <description>aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&gt; 5x the upper limit of normal (ULN) or total bilirubin &gt; 3x the upper limit of normal (ULN)</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function Tests (LFTs) Elevated During or After Echinocandin Therapy</title>
          <description>aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&gt; 5x the upper limit of normal (ULN) or total bilirubin &gt; 3x the upper limit of normal (ULN)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No LFT elevations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt; 5x upper limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt; 5x upper limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin &gt;3x upper limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Type of Adverse Event That Resulted in Echinocandin (EC) Therapy Discontinuation</title>
        <description>The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Type of Adverse Event That Resulted in Echinocandin (EC) Therapy Discontinuation</title>
          <description>The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Adverse Event requiring EC discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver function Test (LFT) increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitization</title>
        <description>Median number of days patients were hospitalized during the study period</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitization</title>
          <description>Median number of days patients were hospitalized during the study period</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="O2" value="28" lower_limit="23" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Neutropenia</title>
        <description>Median number of days patients were neutropenic during the study period</description>
        <time_frame>11/1/2005 - 10/31/2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caspofungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
          </group>
          <group group_id="O2">
            <title>Micafungin Arm</title>
            <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Neutropenia</title>
          <description>Median number of days patients were neutropenic during the study period</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="13" upper_limit="30"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Caspofungin Arm</title>
          <description>All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an ANC &lt; 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.</description>
        </group>
        <group group_id="E2">
          <title>Micafungin Arm</title>
          <description>All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an ANC &lt; 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function test elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST &gt; 5x ULN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="149"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>ALT &gt; 5x ULN</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Total Bilirubin &gt; 3x ULN</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Retrospective, observational, sequential cohort study conducted at a single center. Only adult patients were treated at our institution, so these results cannot be extrapolated to a pediatric population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Kubiak, Principle Investigator</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-8417</phone>
      <email>dwkubiak@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

